• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Quick Take: T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study

byRavi Shah, MD MBA
August 30, 2019
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab

Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic malignancies, however, there are limited data to support this approach in the management of epithelial cancers. Human papillomavirus (HPV)-associated epithelial cancers express viral E6 and E7 oncoproteins, which are absent from healthy tissues, making them appealing targets for T-cell therapies. In this phase I/II single-center trial, 12 patients with metastatic HPV16-positive cancer from any primary tumor site who had received prior platinum-based therapy received autologous genetically engineered T-cells expressing a T-cell receptor (TCR) directed against HPV16 E6 to assess safety, with secondary end points of objective tumor response rate and duration of response. The TCR was a high-avidity TCR directed against an epitope of HPV16 E6 presented by HLA-A*(02:01). Autologous genetically engineered T-cells were created by transducing peripheral blood mononuclear cells with E6 TCR retrovirus, and the conditioning regimen consisted of cyclophosphamide and fludarabine. At baseline, 6 patients had cervical cancer, 4 had anal cancer, 1 had oropharyngeal cancer, and 1 had vaginal cancer. Three of the cervical cancers were adenocarcinomas, and the remainder of the tumors were squamous cell carcinomas (SCC). The median age was 50 years (range 32 to 70 years), and two patients had previously received immunotherapy (one received checkpoint blockade with an anti-PD-1 agent, and one received adoptive T-cell therapy with tumor-infiltrating lymphocytes). Researchers observed no autoimmune adverse events or off-target toxicities attributable to E6 TCR T cells. Two of 12 patients attained objective tumor responses, both of whom had anal SCC (patients 5 and 10). Patient 5 ultimately underwent resection of lung metastases that had regressed with E6 TCR T-cell treatment, and had no evidence of disease 3 years after treatment. This patient was also the only patient with E6 TCR T-cells detected in a post-treatment tumor biopsy. Patient 10 experienced a partial response lasting 3 months before progression of a non-target lesion. All patients demonstrated peripheral blood engraftment with E6 TCR T-cells one month after treatment (median 30%, range 4% to 53%). Whole-exome sequencing of the post-treatment tumor biopsy in a patient who did not respond to treatment revealed a frameshift deletion in IFNGR1, and a tumor of a patient who experienced rapid cancer progression after treatment was found to have allelic imbalance with loss of HLA-A*02:01. Neither of these mutations occurred in Patient 5, and thus they represent potential mechanisms of resistance. Overall, this study indicates that genetically engineered T-cells with virus-specific TCRs are safe and can induce regression in HPV-associated epithelial cancers.

Click to read the study in Journal of Clinical Oncology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cervical cancerchimeric antigen receptor (CAR) T-cell therapyHuman Papilloma Virus (HPV)immunotherapy
Previous Post

#VisualAbstract: Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke

Next Post

Quick Take: Optimal Combination of Compression Rate and Depth During Cardiopulmonary Resuscitation for Functionally Favorable Survival

RelatedReports

Adding sargramostim to ipilimumab may improve survival in advanced melanoma
Chronic Disease

Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

October 12, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

October 11, 2022
PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma
Chronic Disease

Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab

October 7, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Obstetrics and Gynecology Classics

Human papillomavirus infection is associated with adenocarcinoma of the cervix [Classics Series]

September 15, 2022
Next Post
Quick Take: Efficacy of prehospital criteria in identifying trauma patients susceptible to undertriage

Quick Take: Optimal Combination of Compression Rate and Depth During Cardiopulmonary Resuscitation for Functionally Favorable Survival

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Quick Take: Pregnancy duration and endometrial cancer risk

Anti-TNF therapy for inflammatory bowel disease may induce skin lesions

Quick Take: Small Bowel Healing Detected by Endoscopy in Patients With Crohn’s Disease After Treatment With Antibodies Against Tumor Necrosis Factor

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Faecal haemoglobin concentrations associated with mortality and cause of death in colorectal cancer screening
  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options